Sugammadex Use in a Patient with Chronic Renal Failure
Abstract
The introduction of sugammadex in clinical practice could improve the safety profile of muscle relaxants, however, its use in patients with renal diseases is questionable when considering its clearance mechanism, as this could generate some problems. This case report describes a patient with renal disease in whom sugammadex was administered with a quick neuromuscular block reversal without any adverse effects.
References
2. Jones EA, Neuberger J. Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: The Avoidance of opioide withdrawal-like reactions. Q J Med. 2002;95:547-52.
3. Jones EA, Bergasa NV. The pruritus of cholestasis: potencial pathogenic and therapeutic implications of opioids. Gastroenterol. 1995;108:1582-8.
4. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol. 1979;115:1366-7.
5. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrosis. Br Med J. 1988;297:1501-4.
6. Terg R, Coronel E, Sorda J. Oral naltrexone treatment for cholestatic pruritus: a randomized, double blind, crossover study. Hepatology. 2000;32:167.
7. Fariborz MG, Amir T, Hossein F et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol. 2006;12:1125-8.
8. Bergasa NV, Alling DW, Talbot TL et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial. Ann Intern Med. 1995;123:161-7.
9. Jung SI, Cheong HS, Kiun J, et al. Efficacy of naltrexone in the treatment of chronic refractory itching in burn patients: preliminary report of an open trial. J Burn Care Resp. 2009;30:257-60.
10. Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adecuate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol. 2001;13:1393-94.
Downloads
Altmetric
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |